The stock of ICU Medical, Incorporated (NASDAQ:ICUI) hit a new 52-week high and has $231.79 target or 68.00% above today’s $137.97 share price. The 6 months bullish chart indicates low risk for the $2.23 billion company. The 1-year high was reported on Oct, 6 by Barchart.com. If the $231.79 price target is reached, the company will be worth $1.52 billion more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 474,113 shares traded hands or 406.24% up from the average. ICU Medical, Incorporated (NASDAQ:ICUI) has risen 36.99% since March 3, 2016 and is uptrending. It has outperformed by 28.64% the S&P500.
Analysts await ICU Medical, Incorporated (NASDAQ:ICUI) to report earnings on November, 3. They expect $0.92 earnings per share, up 5.75% or $0.05 from last year’s $0.87 per share. ICUI’s profit will be $14.87M for 37.49 P/E if the $0.92 EPS becomes a reality. After $0.98 actual earnings per share reported by ICU Medical, Incorporated for the previous quarter, Wall Street now forecasts -6.12% negative EPS growth.
ICU Medical, Incorporated (NASDAQ:ICUI) Ratings Coverage
Out of 4 analysts covering ICU Medical (NASDAQ:ICUI), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $142 is the highest target while $124 is the lowest. The $130.80 average target is -5.20% below today’s ($137.97) stock price. ICU Medical has been the topic of 8 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of ICU Medical, Incorporated (NASDAQ:ICUI) earned “Buy” rating by TH Capital on Friday, November 6. The rating was maintained by Piper Jaffray on Tuesday, August 11 with “Overweight”. On Friday, November 6 the stock rating was maintained by Roth Capital with “Buy”. The firm has “Buy” rating by Gabelli given on Friday, March 11. TH Capital maintained ICU Medical, Incorporated (NASDAQ:ICUI) on Tuesday, August 11 with “Buy” rating. As per Tuesday, August 11, the company rating was maintained by Roth Capital. Zacks upgraded ICU Medical, Incorporated (NASDAQ:ICUI) on Monday, August 17 to “Hold” rating.
According to Zacks Investment Research, “ICU Medical, Inc., together with its wholly-owned subsidiary Budget Medical Products, Inc. is a leader in the development, manufacture and sale of proprietary, disposable medical connection systems for use in intravenous therapy applications. The company’s intravenous connectors are designed to prevent accidental disconnection’s of intravenous lines and to protect healthcare workers and their patients from the spread of infectious diseases such as Hepatitis B and Human Immunodeficiency Virus by significantly reducing the risk of accidental needlesticks.”
Insitutional Activity: The institutional sentiment increased to 1.02 in Q2 2016. Its up 0.11, from 0.91 in 2016Q1. The ratio is positive, as 14 funds sold all ICU Medical, Incorporated shares owned while 76 reduced positions. 20 funds bought stakes while 72 increased positions. They now own 14.20 million shares or 0.50% more from 14.13 million shares in 2016Q1.
Hsbc Hldgs Public Ltd Liability Com holds 0% of its portfolio in ICU Medical, Incorporated (NASDAQ:ICUI) for 2,626 shares. The Virginia-based Virginia Retirement Systems Et Al has invested 0.01% in ICU Medical, Incorporated (NASDAQ:ICUI). Strs Ohio holds 0.01% or 10,200 shares in its portfolio. Teton accumulated 0.08% or 7,714 shares. Keybank Natl Association Oh has 11,400 shares for 0.01% of their US portfolio. Robeco Institutional Asset Bv holds 7,844 shares or 0.01% of its portfolio. Morgan Dempsey Management Ltd Limited Liability Company has invested 0.89% of its portfolio in ICU Medical, Incorporated (NASDAQ:ICUI). Savings Bank Of America De has 0% invested in the company for 42,325 shares. Blackrock Japan Commerce Limited has 0% invested in the company for 8,879 shares. Fisher Asset Management Limited Liability Corp has 0.01% invested in the company for 31,000 shares. Price T Rowe Assoc Incorporated Md has 194,450 shares for 0% of their US portfolio. Goldman Sachs Grp has invested 0% of its portfolio in ICU Medical, Incorporated (NASDAQ:ICUI). Renaissance Techs Ltd last reported 793,100 shares in the company. The Vermont-based Tru Of Vermont has invested 0% in ICU Medical, Incorporated (NASDAQ:ICUI). National Bank Of Montreal Can has 0% invested in the company for 1,172 shares.
Insider Transactions: Since April 11, 2016, the stock had 0 insider purchases, and 15 sales for $16.94 million net activity. On Monday, September 12 RIGGS STEVEN sold $5.45M worth of the stock or 44,739 shares. Another trade for 28,526 shares valued at $3.47M was sold by Lamb Scott E. SAUCEDO JOSEPH R sold $196,875 worth of ICU Medical, Incorporated (NASDAQ:ICUI) on Tuesday, May 10. $1.77M worth of ICU Medical, Incorporated (NASDAQ:ICUI) shares were sold by McGrody Kevin J. The insider SWINNEY ROBERT S sold $190,031. On Wednesday, August 24 Jain Vivek sold $903,019 worth of the stock or 7,268 shares. Another trade for 18,559 shares valued at $2.31 million was sold by McCall Thomas D.
More recent ICU Medical, Incorporated (NASDAQ:ICUI) news were published by: Streetinsider.com which released: “ICU Medical (ICUI) to Acquire Pfizer’s (PFE) Hospira Infusion Systems Business …” on October 06, 2016. Also Reuters.com published the news titled: “ICU Medical to buy Pfizer’s infusion therapy business for $1 bln” on October 06, 2016. Prnewswire.com‘s news article titled: “B. Braun and ICU Medical Sign Expanded Long-Term International Distribution …” with publication date: March 21, 2016 was also an interesting one.
ICUI Company Profile
ICU Medical, Inc., incorporated on January 9, 1992, is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The Firm operates through the segment, which is engaged in the development, manufacturing and sale of medical technologies used in infusion therapy, critical care and oncology applications. The Company’s products are used in acute care hospitals and ambulatory clinics in over 60 countries around the world.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.